Replimune Group, Inc.

US$21.62As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:REPLHealthcare
Country USA
PE (Fwd) •••
TSR 8Y CAGR 4.53%
Div yield —
ROE (115.80%)
Biotechnology
Beta (5Y) 0.93
PE TTM —
TSR TTM 122.20%
Mkt cap US$2.050B
ROIC (49.95%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$28
28.83%
(50.87%)
Hold 7|12|5|9|4
3Q26
4Q26
1Q27
2Q27
Earnings per share$
0.33
0.35
0.37
0.36
25.46%
36.46%
40.66%
24.07%
Revenue$M
115.0
112.3
112.4
113.6
12.32%
4.63%
0.05%
(2.59%)
Peers (US$2.050B)
Cap (US$)
PE
2.071B
5.627x
Capital
TTM
5Y
10Y
Leveragex
0.236
(0.207)
(0.164)
EBIT/Intx
2.200
0.161
0.170
Own earn%
(221.42)
(5.58)
(3.37)
Sh yield%
29.80
53.30
54.60
Owners
Insiders/Inst%
1.63
31.62
Short interest%
2.06
SBC / revenue%
0.68
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
25–30
$1 testx
0.0
Incr. ROIC%
4